Home › Kidney Cancer (Renal Cell Carcinoma) › Michigan › Flint
Kidney Cancer (Renal Cell Carcinoma) clinical trials in Flint, MI
3 studies for Kidney Cancer (Renal Cell Carcinoma) are looking for participants at sites in and around Flint (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Cancer Hematology Centers - Flint, Flint
- Genesee Hematology Oncology PC, Flint
- Genesys Hurley Cancer Institute, Flint
- and 1 more
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- Cancer Hematology Centers - Flint, Flint
- Genesys Hurley Cancer Institute, Flint
- Hurley Medical Center, Flint
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RecruitingPhase 3
- Cancer Hematology Centers - Flint, Flint
- Genesys Hurley Cancer Institute, Flint
Kidney Cancer (Renal Cell Carcinoma) trials in other cities
- Houston, TX35 studies
- New York City, NY27 studies
- Dallas, TX23 studies
- Nashville, TN23 studies
- St. Louis, MO23 studies
- Los Angeles, CA20 studies
- Boston, MA16 studies
- Baldwin Park, CA16 studies
- Pittsburgh, PA15 studies
- Philadelphia, PA15 studies
- Queens, NY15 studies
- Rochester, MN14 studies
Other studies in Flint
- Lung Cancer10 studies
- Non-Small Cell Lung Cancer9 studies
- Breast Cancer9 studies
- Prostate Cancer7 studies
- Acute Myeloid Leukemia6 studies
- Colorectal Cancer6 studies
- Cancer (all types)5 studies
- Lupus4 studies
- Head and Neck Squamous Cell Carcinoma4 studies
- Hypopharyngeal Cancer4 studies
- Laryngeal Cancer4 studies
- Oral Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.